Exelixis, Inc.
zanzalintinib
previously treated metastatic colorectal cancer
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on zanzalintinib for previously treated metastatic colorectal cancer is expected Date TBD.
Primary source
· SEC 8-K
verified 15h ago
“The U.S. Food and Drug Administration (FDA) is currently reviewing Exelixis' New Drug Application (NDA) for this proposed indication, when used in combination with atezolizumab (Tecentriq [...] ease,”